Survival following treatment for intracranial ependymoma: a review.
The actual definition of survival rates following treatment for intracranial ependymomas is substantially influenced by the strict interaction among different factors. Age, location, and grading, for example, act together, negatively influencing the prognosis of younger children also invariably influenced by the more demanding role of surgery and the still limited use, up to recently, of radiotherapy under 3 years of age. In the same direction, the worse prognosis in most series of infratentorial ependymomas if compared with their supratentorial counterpart should be cautiously considered, midline posterior fossa tumors having completely different implications from those originating or predominantly extending to the cerebellopontine angle, where the extent of surgery has more invariably to compare with patients' quality of life. New radiotherapic regimens and their applications in infancy are promisingly demonstrating an improvement of present prognostic criteria, with the limit of still insufficient information on their long-term secondary effects. Similarly, molecular biology research studies, though still in their preclinical stage, are prompting to change the concept of a substantially chemoresistant tumor helping to stratify these lesions with the final aim of targeted pharmacological therapies. In the present review paper, we investigated singularly the role that the more commonly considered prognostic factors have had in the literature on survival of children affected by intracranial ependymomas, trying to elucidate their cumulative effect on the actual knowledge of this issue.
Tamburrini
G
G
Pediatric Neurosurgery, Institute of Neurosurgery, Catholic University Medical School, Largo A. Gemelli, 8, 00168, Rome, Italy. gianpiero.tamburrini@rm.unicatt.it
D'Ercole
M
M
Pettorini
B L
BL
Caldarelli
M
M
Massimi
L
L
Di Rocco
C
C
D001932:Brain Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D002648:Child; D004806:Ependymoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D016896:Treatment Outcome